Skip to Content
Merck
All Photos(3)

Documents

739952

Sigma-Aldrich

Resomer® RG 503, Poly(D,L-lactide-co-glycolide)

lactide:glycolide 50:50, ester terminated, Mw 24,000-38,000

Synonym(s):

PLGA, RESOMER® RG 503

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
26780-50-7
UNSPSC Code:
12162002
NACRES:
NA.23

form

amorphous

feed ratio

lactide:glycolide 50:50

mol wt

Mw 24,000-38,000

degradation timeframe

<3 months

viscosity

0.32-0.44 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 44-48 °C

storage temp.

2-8°C

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

Related Categories

Application

Controlled release

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kaiping Wang et al.
Journal of microencapsulation, 36(4), 356-370 (2019-06-14)
Here, we have successfully synthesised and purified multifunctional PLGA-based nanoparticles by the co-encapsulation of an anticancer drug (tetrandrine) and a magnetic material (Fe3O4). The obtained Tet-Fe3O4-PLGA NPs had a uniform spherical shape with a particle size of approximately 199 nm and
William A Lackington et al.
Journal of controlled release : official journal of the Controlled Release Society, 304, 51-64 (2019-05-06)
Neurotrophic factor delivery via biodegradable nerve guidance conduits may serve as a promising treatment for the repair of large peripheral nerve defects. However, a platform for controlled delivery is required because of their short in vivo half-life and their potential
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Vanna Sanna et al.
International journal of nanomedicine, 7, 5501-5516 (2012-10-25)
Resveratrol, like other natural polyphenols, is an extremely photosensitive compound with low chemical stability, which limits the therapeutic application of its beneficial effects. The development of innovative formulation strategies, able to overcome physicochemical and pharmacokinetic limitations of this compound, may
View All Related Papers

Articles

RESOMER® - Biodegradable Polymers for Sutures, Medical Devices, Drug Delivery Systems and Tissue Engineering

Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.

Poly(Glycerol Sebacate) in Tissue Engineering

Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.

Biodegradable Polyester Nanoparticle Formation

AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.

Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-Targeted Delivery and Immunomodulation

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service